GeneWorld Co., Ltd., Ho Chi Minh   Report issue

For profit Phase 2
Founded: Ho Chi Minh City Vietnam (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2013
NCT02142842
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

GeneWorld Ltd Co, Ho Chi Minh city, Viet Nam

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic adipose derived mesenchymal stem cell (2 trials)

platelet rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases, Obstructive (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2